Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.730
-0.009 (-1.20%)
At close: Dec 5, 2025, 4:00 PM EST
0.713
-0.017 (-2.38%)
After-hours: Dec 5, 2025, 7:05 PM EST
Cytosorbents Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cytosorbents stock have an average target of 5.38, with a low estimate of 0.75 and a high estimate of 10. The average target predicts an increase of 636.89% from the current stock price of 0.73.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytosorbents stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,269.68% | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $1 → $0.75 | Hold | Maintains | $1 → $0.75 | +2.73% | Nov 14, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,269.68% | Sep 16, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,269.68% | Aug 20, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +1,269.68% | Aug 8, 2025 |
Financial Forecast
Revenue This Year
38.98M
from 35.59M
Increased by 9.51%
Revenue Next Year
48.49M
from 38.98M
Increased by 24.40%
EPS This Year
-0.15
from -0.38
EPS Next Year
-0.06
from -0.15
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 40.6M | 55.9M | ||||
| Avg | 39.0M | 48.5M | ||||
| Low | 37.0M | 41.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 14.0% | 43.5% | ||||
| Avg | 9.5% | 24.4% | ||||
| Low | 4.1% | 5.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.13 | -0.02 | |
| Avg | -0.15 | -0.06 | |
| Low | -0.18 | -0.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.